Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 210

1.

Nursing implications for the lifelong management of tuberous sclerosis complex.

Agricola K, Tudor C, Krueger D, Franz DN.

J Neurosci Nurs. 2013 Aug;45(4):226-42. doi: 10.1097/JNN.0b013e3182986146. Review.

PMID:
23812052
2.

Emerging treatments in the management of tuberous sclerosis complex.

Kohrman MH.

Pediatr Neurol. 2012 May;46(5):267-75. doi: 10.1016/j.pediatrneurol.2012.02.015. Review.

PMID:
22520346
3.

Everolimus: an mTOR inhibitor for the treatment of tuberous sclerosis.

Franz DN.

Expert Rev Anticancer Ther. 2011 Aug;11(8):1181-92. doi: 10.1586/era.11.93. Review.

PMID:
21916571
4.

Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex.

MacKeigan JP, Krueger DA.

Neuro Oncol. 2015 Dec;17(12):1550-9. doi: 10.1093/neuonc/nov152. Review.

5.

Tuberous sclerosis.

Curatolo P, Maria BL.

Handb Clin Neurol. 2013;111:323-31. doi: 10.1016/B978-0-444-52891-9.00038-5. Review.

PMID:
23622183
6.

Mechanistic target of rapamycin (mTOR) in tuberous sclerosis complex-associated epilepsy.

Curatolo P.

Pediatr Neurol. 2015 Mar;52(3):281-9. doi: 10.1016/j.pediatrneurol.2014.10.028. Review.

PMID:
25591831
7.
8.

Tuberous sclerosis complex-associated angiomyolipomas: focus on mTOR inhibition.

Budde K, Gaedeke J.

Am J Kidney Dis. 2012 Feb;59(2):276-83. doi: 10.1053/j.ajkd.2011.10.013. Review.

PMID:
22130643
9.

Everolimus in tuberous sclerosis patients with intractable epilepsy: a treatment option?

Wiegand G, May TW, Ostertag P, Boor R, Stephani U, Franz DN.

Eur J Paediatr Neurol. 2013 Nov;17(6):631-8. doi: 10.1016/j.ejpn.2013.06.002.

PMID:
23845174
10.

Everolimus in immunosuppressive treatment after kidney transplantation in a patient with tuberous sclerosis: case report.

Tarasewicz A, Dębska-Ślizień A, Bułanowski M, Więcek A, Rutkowski B.

Transplant Proc. 2014 Oct;46(8):2912-5. doi: 10.1016/j.transproceed.2014.09.065.

PMID:
25380949
11.

Rapamycin as a therapy of choice after renal transplantation in a patient with tuberous sclerosis complex.

Tarasewicz A, Debska-Slizień A, Konopa J, Zdrojewski Z, Rutkowski B.

Transplant Proc. 2009 Nov;41(9):3677-82. doi: 10.1016/j.transproceed.2009.06.227.

PMID:
19917366
12.

Is mTOR inhibition a systemic treatment for tuberous sclerosis?

Moavero R, Coniglio A, Garaci F, Curatolo P.

Ital J Pediatr. 2013 Sep 17;39:57. doi: 10.1186/1824-7288-39-57. Review.

14.

Regression of symptomatic multiple cardiac rhabdomyomas associated with tuberous sclerosis complex in a newborn receiving everolimus.

Doğan V, Yeşil Ş, Kayalı Ş, Beken S, Özgür S, Ertuğrul İ, Bozkurt C, Örün UA, Karademir S.

J Trop Pediatr. 2015 Feb;61(1):74-7. doi: 10.1093/tropej/fmu056.

PMID:
25344617
15.

The mTOR inhibitor rapamycin significantly improves facial angiofibroma lesions in a patient with tuberous sclerosis.

Hofbauer GF, Marcollo-Pini A, Corsenca A, Kistler AD, French LE, Wüthrich RP, Serra AL.

Br J Dermatol. 2008 Aug;159(2):473-5. doi: 10.1111/j.1365-2133.2008.08677.x.

PMID:
18547304
16.

Efficacy of combined inhibition of mTOR and ERK/MAPK pathways in treating a tuberous sclerosis complex cell model.

Mi R, Ma J, Zhang D, Li L, Zhang H.

J Genet Genomics. 2009 Jun;36(6):355-61. doi: 10.1016/S1673-8527(08)60124-1.

PMID:
19539245
17.

[Autism, epilepsy and tuberous sclerosis complex: a functional model linked to mTOR pathway].

García-Peñas JJ, Carreras-Sááez I.

Rev Neurol. 2013 Feb 22;56 Suppl 1:S153-61. Spanish.

18.

Mammalian target of rapamycin inhibitors for treatment in tuberous sclerosis.

Kim WS.

Korean J Pediatr. 2011 Jun;54(6):241-5. doi: 10.3345/kjp.2011.54.6.241. Retraction in: Rha YH. Korean J Pediatr. 2013 Jun;56(6):269.

19.

Regression of subependymal giant cell astrocytomas with RAD001 (Everolimus) in tuberous sclerosis complex.

Yalon M, Ben-Sira L, Constantini S, Toren A.

Childs Nerv Syst. 2011 Jan;27(1):179-81. doi: 10.1007/s00381-010-1222-y.

PMID:
20703486
20.
Items per page

Supplemental Content

Support Center